
What is CPIC?
The Clinical Pharmacogenetics Implementation Consortium (CPIC®) is an international consortium of individual volunteers and a small dedicated staff who are interested in facilitating use of pharmacogenetic tests for patient care.
One barrier to implementation of pharmacogenetic testing in the clinic is the difficulty in translating genetic laboratory test results into actionable prescribing decisions for affected drugs.
CPIC’s goal is to address this barrier to clinical implementation of pharmacogenetic tests by creating, curating, and posting freely available, peer-reviewed, evidence-based, updatable, and detailed gene/drug clinical practice guidelines (click here for all CPIC publications). CPIC guidelines follow standardized formats, include systematic grading of evidence and clinical recommendations, use standardized terminology, are peer-reviewed, and are published in a leading journal (in partnership with Clinical Pharmacology and Therapeutics) with simultaneous posting to cpicpgx.org, where they are regularly updated.
CPIC started as a shared project between PharmGKB and the Pharmacogenomics Research Network (PGRN) in 2009. CPIC guidelines are indexed in PubMed as clinical guidelines, endorsed by ASHP and ASCPT, and referenced in ClinGen and PharmGKB.
Additionally, the College of American Pathologists (CAP) has stated: “CAP applauds and supports the objectives, processes and work completed as of December 2018 by the Clinical Pharmacogenetics Implementation Consortium (CPIC®). These efforts will help clinicians, laboratories, health care providers and vendors.”
CPIC resources are freely available under a Creative Commons public domain license.
Read the license page for more details.
Team
CPIC Co-Principal Investigators
Kelly E. Caudle, Pharm.D., Ph.D.
St. Jude Children’s Research Hospital
Teri E. Klein, Ph.D.
Stanford University
Co-Investigator
Mary V. Relling, Pharm.D.
St. Jude Children’s Research Hospital
CPIC Informatics Co-Directors
Michelle Whirl-Carrillo, Ph.D.
Stanford University
James M. Hoffman, Pharm.D.
St. Jude Children’s Research Hospital
Stanford CPIC Coordinator
Michelle Whirl-Carrillo, Ph.D.
Stanford University
Steering Committee
Teri E. Klein, Ph.D.
Stanford University
Kelly E. Caudle, Pharm.D., Ph.D.
St. Jude Children’s Research Hospital
Michelle Whirl-Carrillo, Ph.D.
Stanford University
Mary V. Relling, Pharm.D.
St. Jude Children’s Research Hospital
Dan M. Roden, M.D.
Vanderbilt University
Rachel F. Tyndale, Ph.D.
University of Toronto and CAMH
Larisa Cavallari, Pharm.D.
University of Florida
Stuart A. Scott, Ph.D.
Stanford University and Stanford Healthcare
Sara Van Driest, M.D., Ph.D.
Vanderbilt University
Scientific Advisory Board
Julie A. Johnson, Pharm.D.
University of Florida
Gwendolyn A. McMillin, Ph.D.
ARUP Laboratories
Robert Nussbaum, M.D.
University of California, San Francisco
Heidi Rehm, Ph.D.
Partners Healthcare
Marc S. Williams, M.D.
Geisinger
Sandy Aronson
Partners Personalized Medicine
Justin B. Starren, M.D., Ph.D.
Northwestern University
Houda Hachad, Pharm.D., M. Res.
AccessDx/Medtek21
Andrea Gaedigk, Ph.D.
Children’s Mercy
News & Announcements
- A recent paper highlights new variants and genes associated with severe fluoropyrimidine-related toxicity in patients who were genotyped as negative for the four DPYD variants the European Medicines Agency recommends testing for.Online ahead of print in the Human Genomics journal is De Mattia et al "The burden of rare variants in DPYS gene is a […]
- In collaboration with CPIC, PharmGKB, PharmCAT and PharmVar, the University of Pennsylvania, Penn Center for Precision Medicine will be hosting the ClinPGx 2024: Knowledge, Implementation, Education meeting June 20th and 21st, 2024 in Philadelphia, PA. The meeting will provide educational content to cover all aspects of PGx implementation including knowledgebases, implementation strategies, informatics, use of AI in precision […]
- We are happy to announce the publication of our latest research article in the American Journal of Human Genetics (AJHG), titled “Frequencies of Pharmacogenomic Alleles across Biogeographic Groups in a Large-Scale Biobank.” The paper is now available online on the AJHG website.Genetic biobanks provide rich data sets to investigate population-specific pharmacogenomic (PGx) allele frequencies and […]
- Substance abuse disorders are a significant public health cost [PMID: 34453125]. Prescribers have limited choices for pharmaceutical therapies with only three FDA-approved choices for alcohol use disorder and zero for cocaine use disorder. Disulfiram is an FDA-approved treatment for alcohol use disorder which is also used for cocaine use disorder. There are some preliminary studies […]
- Dan Hertz (DLHertz@med.umich.edu) and the DPYD Implementation Team are collecting information from sites and clinicians in the USA that conduct DPYD genetic testing prior to fluoropyrimidine chemotherapy treatment. If this applies to you, please complete this brief (